Renal Denervation Devices Market Size, Share & Industry Analysis, By Product (Single electrode, Multi Electrode, Irrigated Catheter, Non irrigated catheter, Others), By Technology (Radio Frequency Ablation, Ultrasound Energy-based RDN, Brachytherapy, Chemical Ablation, Others), By End User (Hospitals, Cardiovascular research centre, Others) And Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
Renal denervation is the minimally invasive procedure used to treat resistant hypertension. Resistant hypertension is the condition where patients are non-responsive to repetitive use of oral anti-hypertension drugs.
Increase in chronic and lifestyle diseases such as diabetes and obesity along with increase in geriatric population are the leading causes of resistant hypertension. This increase in prevalence of resistant hypertension is leading to increase in number of patients seeking treatment. This, along with rising preference of healthcare providers towards minimally invasive procedures for treatment of resistant hypertension using renal denervation technique, is driving the demand of renal denervation devices.
However, lack of trained professionals especially in emerging countries, is responsible for limited penetration of the renal denervation procedures in these countries. This along with lower diagnosis rates among general population in these countries is leading to limited demand for renal denervation devices market.
Key Market Driver -
Rising prevalence of hypertension, preference for minimally invasive procedure, increase in geriatric, obese and diabetic population.
Key Market Restraint -
Lack of trained professionals, changes in renal anatomy, requirement of long term follow-up after procedure, potential risk of procedure.
Market Segmentation:
Globally renal denervation devices market can be segmented on the basis of product, technology, end user and geography. On the basis of product, it can be segmented as single electrode, multi electrode, irrigated catheter, non- irrigated catheter. Based on technology it can be segmented as radio frequency ablation, ultrasound energy based RDN, brachytherapy (Beta Radiation), chemical ablation. On the basis of end user, it can be segmented as hospitals, cardiovascular research center and others. Geographically, the Renal Denervation Devices market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
Key Players Covered:
Some of the major companies in renal denervation devices market are Medtronic, Johnson & Johnson Services, Inc., Boston Scientific Corporation, ReCor Medical, Inc., Terumo Corporation, Ablative Solutions, Inc., Mercator MedSystems, SympleSurgical Inc.
Key Insights:
- Impact of Covid-19 on the Market
- Technological Advancements in Renal Denervation Devices
- New Product Launches
- Key Industry Developments Mergers, Acquisitions, And Collaboration
Regional Analysis:
Geographically, the renal denervation devices market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Growth of the market in North America is attributed to higher diagnosis and treatment rates among patients in the U.S., along with adoption of advanced devices in the country. Europe is expected to hold the second largest market share during the forecast period. Increasing preference for minimally-invasive procedures for treatment of resistant hypertension, is likely to fuel the market growth in this region. On the other hand, Asia Pacific is expected to grow with the highest growth rate during the forecast period owing to the increasing adoption of advanced devices and techniques for the treatment of resistant hypertension. The market in Latin America and the Middle East & Africa are expected to showcase substantial growth during the forecast period.
To gain extensive insights into the market, Request for Customization
Segmentation
ATTRIBUTES | DETAILS |
By Product |
|
By Technology |
|
By End User |
|
By Geography |
|
Renal Denervation Devices Market Industry Developments
- In April 2021, Brattea, a leading company in renal denervation in China, completes over $US20 Million led by Kuanping capital.
- In December 2020, FDA has granted breakthrough therapy device designation to two renal denervation systems ReCor Medical, Inc. and SoniVie.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
